Identification of an  EPC2-PHF1  fusion transcript in low-grade endometrial stromal sarcoma

Marta Brunetti; Ludmila Gorunova; Ben Davidson; Sverre Heim; Ioannis Panagopoulos; Francesca Micci

doi:10.18632/oncotarget.24969

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma

Marta Brunetti, Ludmila Gorunova, Ben Davidson, Sverre Heim, Ioannis Panagopoulos and Francesca Micci _

PDF | HTML | How to cite

Oncotarget. 2018; 9:19203-19208. https://doi.org/10.18632/oncotarget.24969

Metrics: PDF 2529 views | HTML 3225 views | ?

Abstract

Marta Brunetti1, Ludmila Gorunova1, Ben Davidson2,3, Sverre Heim1,3, Ioannis Panagopoulos1 and Francesca Micci1

1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

2Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

3Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

Correspondence to:

Francesca Micci, email: [email protected]

Keywords: fusion gene; EPC2; PHF1; RNA sequencing; low-grade endometrial stromal sarcoma

Received: February 13, 2018 Accepted: March 16, 2018 Published: April 10, 2018

ABSTRACT

Recurrent chromosomal translocations leading to gene fusion formation have been described in uterine sarcomas, including low-grade endometrial stromal sarcoma (LG-ESS). Involvement of the PHF1 gene in chromosomal rearrangements targeting band 6p21 has been found in LG-ESS with different partners from JAZF1 mapping in 7p15, to EPC1 from 10p11, MEAF6 from 1p34, and BRD8 from 5q31.

In the present study, RNA sequencing of a LG-ESS showed a novel recombination of PHF1 with the Enhancer of Polycomb homolog 2 (EPC2). RT-PCR followed by Sanger sequencing and FISH analysis confirmed the EPC2-PHF1 fusion transcript.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24969

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma

Abstract